Skip to main content

Table 4 Clinical adverse events in the per protocol population

From: Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study

 

ASAQ (number of patients)

AL (number of patients)

P

D0

D1

D2

D3

D7

Total

%

D0

D1

D2

D3

D7

Total

%

Adverse effects

129

125

123

119

114

 

133

132

130

125

126

  

Fatigue

2

18

19

25

1

65

10.7

3

14

12

5

4

38

5.9

0.02

Anorexia

3

1

1

2

2

9

1.5

0

1

1

2

1

5

0.8

0.2

Vomiting

8

10

4

4

2

28

4.6

11

9

5

0

1

26

4.0

0.6

Abdominal pain

3

6

4

4

2

19

3.1

2

2

2

3

5

14

2.2

0.3

Diarrhoea

2

3

4

0

2

11

1.8

9

2

1

0

0

12

1.9

0.9

Nausea

0

3

1

2

0

6

1

0

0

1

0

1

2

0.3

0.2

Headache

3

3

1

0

2

9

1.5

0

2

2

2

2

8

1.2

0.7

Jaundice

0

1

0

2

4

7

1.1

1

0

0

1

1

3

0.5

0.3

Dizziness

0

1

3

3

0

7

1.1

0

0

1

1

0

2

0.3

0.1

Pruritus

0

0

2

1

1

4

0.7

0

0

1

0

0

1

0.2

0.3

Rashes

0

0

0

0

1

1

0.2

0

0

0

0

0

0

0

  1. ASAQ artesunate-amodiaquine, AL artemether-lumefantrine